Capivasertib with paclitaxel for previously untreated locally advanced or metastatic triple-negative breast cancer

Capivasertib with paclitaxel is currently in clinical development for previously untreated locally
advanced (inoperable) or metastatic triple-negative breast cancer (TNBC). TNBC is a rare form of
breast cancer where the tumour cells do not have receptors for oestrogen, progesterone, or the
human epidermal growth factor receptor 2 (HER2) protein. Symptoms of TNBC include: a new
lump or thickening in the breast or armpit, a change in size, shape or feel of the breast and skin
changes in the breast. Established risk factors of breast cancer include age, early onset of
menstruation, late menopause, older age at first completed pregnancy, and a family history. There
is a need for novel therapies as treatment options for TNBC are limited to sequential
chemotherapy which is often associated with short-lived benefits and higher susceptibility to
resistance.